Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • AB Science

    Biogen Idec building

    Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

    - PMLiVE

    Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m

    The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease

    - PMLiVE

    Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

    The neurodegenerative disease affects approximately 30,000 people in the US

    - PMLiVE

    Researchers develop new approach to target cells affected by motor neurone disease

    The technique could lead to safer and more effective gene therapies for the neurodegenerative disease

    - PMLiVE

    LifeArc and King’s College London partner to accelerate treatment for motor neurone disease

    The rare neurodegenerative disease affects one in every 300 people in the UK

    - PMLiVE

    NIHR partners with Motor Neurone Disease Association for MND research

    The partnership will speed up the discovery of treatments and insights for MND

    - PMLiVE

    Innovate UK awards Sano Genetics £330,000 grant for ALS study

    The project will chart the psychological impacts of having a genetic predisposition to ALS

    Biogen Idec building

    Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases

    - PMLiVE

    Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

    The neurodegenerative disease affects approximately 27,000 people in the US

    - PMLiVE

    UK Government commit £50m to motor neurone disease research

    The pledged funding is being placed into the hands of researchers ‘as quickly as possible’

    - PMLiVE

    Verge Genomics begins human trials with AI-sourced ALS drug

    VRG50635 was discovered by the company’s all-in-human, AI-powered platform

    - PMLiVE

    Biogen’s tofersen shows promise in rare form of ALS in new data analysis

    Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links